Trial Profile
A 12 Week, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study of SYMBICORT pMDI Administered Once Daily in Children and Adolescents 6 to 15 Years of Age With Asthma - SPROUT
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2010
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPROUT
- Sponsors AstraZeneca
- 01 Sep 2010 Results have been published in Pediatrics.
- 12 Jun 2008 New trial record.
- 04 Jun 2008 sNAD submitted to FDA according to AstraZeneca media release.